#### Check for updates

#### OPEN ACCESS

EDITED BY Monique Stins, Johns Hopkins University, United States

#### REVIEWED BY

Aye-Mu Myint, Maastricht University, Netherlands Gilberto Pérez-Sánchez, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico Dennis John Grab, Uniformed Services University, United States

#### \*CORRESPONDENCE

Letusa Albrecht letusa.albrecht@fiocruz.br Raffael Massuda rmassuda@gmail.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 22 July 2024 ACCEPTED 20 March 2025 PUBLISHED 10 April 2025

#### CITATION

Cavalari VC, Cardoso Garcia LF, Massuda R and Albrecht L (2025) *Toxoplasma gondii*, endothelial cells and schizophrenia: is it just a barrier matter?. *Front. Cell. Infect. Microbiol.* 15:1468936. doi: 10.3389/fcimb.2025.1468936

#### COPYRIGHT

© 2025 Cavalari, Cardoso Garcia, Massuda and Albrecht. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# *Toxoplasma gondii*, endothelial cells and schizophrenia: is it just a barrier matter?

Victoria Cruz Cavalari<sup>1†</sup>, Luiz Fernando Cardoso Garcia<sup>1†</sup>, Raffael Massuda<sup>2\*</sup> and Letusa Albrecht<sup>1\*</sup>

<sup>1</sup>Laboratório de Pesquisa em Apicomplexa – Instituto Carlos Chagas, Fundação Oswaldo Cruz, Curitiba, Paraná, Brazil, <sup>2</sup>Departamento de Medicina Forense e Psiquiatria da Universidade Federal do Paraná, Curitiba, Paraná, Brazil

Toxoplasma gondii is an obligatory intracellular parasite responsible for causing toxoplasmosis. It is estimated that approximately one-third of the world's population has positive serology for toxoplasmosis. Acute T. gondii infection often results in subtle symptoms because of its nonspecific nature. Owing to immune pressure, parasites tend to encyst and persist in different tissues and organs, such as the brain, chronicling the infection. While most chronically infected individuals do not develop significant symptoms, the parasite can affect the central nervous system (CNS), leading to symptoms that range from dizziness to behavioral changes. To reach the CNS, parasites must overcome the blood-brain barrier, which is composed primarily of endothelial cells. While these cells are typically efficient at separating blood elements from the CNS, in T. gondii infection, they not only permit parasitic colonization of the CNS but also contribute to an inflammatory profile that may exacerbate previously established conditions at both the local CNS and systemic levels. An increasing body of research has demonstrated a potential link between the CNS, infection by T. gondii and the cellular or humoral response to infection, with the worsening of psychiatric conditions, such as schizophrenia. Therefore, continually advancing research aimed at understanding and mitigating the relationship between parasitic infection and schizophrenia is imperative.

KEYWORDS

toxoplasmosis, schizophrenia, endothelial cell, neuroinflammation, Toxoplasma gondii

# Introduction

*Toxoplasma gondii* (*T. gondii*) is a parasite belonging to the phylum Apicomplexa. It is the etiological agent of toxoplasmosis, a disease that holds considerable public health significance, largely because of its morbidity. Approximately 30% of the global human population carries *T. gondii* (Safarpour et al., 2020). In healthy individuals, toxoplasmosis often remains asymptomatic. However, immunocompromised individuals can experience various manifestations ranging from headaches and elevated liver enzymes to lymph node

enlargement, fever, pneumonia, and even central nervous system (CNS) involvement (Bossi et al., 1998; Carme et al., 2002).

During *T. gondii* infection, the parasite has the capacity to breach the endothelial barrier, allowing it to infiltrate various organs or tissues, including the brain (Lachenmaier et al., 2011; Konradt et al., 2016; Baba et al., 2017). Neurotoxoplasmosis is characterized by the presence of *T. gondii* cysts in the brains of infected individuals (Mesquita et al., 2010; Alvarado-Esquivel et al., 2015). Several studies have evaluated neurological changes caused by *T. gondii* infection, and one of the most studied relationships is between *T. gondii* infection and schizophrenia (Alvarado-Esquivel et al., 2011; Dickerson et al., 2014). Although the relationship between *T. gondii* infection and neurological disorders has been studied for decades (Navia et al., 1986; Khalid et al., 2023), the precise relationship between *T. gondii* infection and the development of schizophrenia remains uncertain.

Given the significance attributed to toxoplasmosis and its potential correlation with the onset or exacerbation of psychiatric disorders, we have undertaken this literature review to ascertain the current state of research pertaining to toxoplasmosis, the CNS endothelium and its influence on the progression of schizophrenia.

# Endothelium

Endothelial cells derived from the embryonic mesoderm are vital for body homeostasis (Zovein et al., 2008). Although the endothelium shares a common origin, it exhibits significant heterogeneity throughout the human body, as will be briefly discussed in this section.

The endothelium can be classified as continuous when its cells are joined by tight junctions, forming a protective barrier, as seen in blood vessels, the heart, lungs, skin, and the central nervous system (CNS). The fenestrated endothelium, with transcellular pores, allows solute exchange in organs like the kidneys and liver. In contrast, the fenestrated endothelium, featuring larger gaps or spaces, enables the passage of large molecules and is found in the sinusoids of the liver, bone marrow, and spleen (Margreet De Leeuw et al., 1990; Price et al., 2020; Su et al., 2021; Zuo et al., 2021). Functionally, it regulates vascular permeability and produces vasoactive substances such as nitric oxide and prostacyclin, influencing blood flow and pressure (Iwabayashi et al., 2012; Mitchell et al., 2021). Dysfunction contributes to cardiovascular diseases such as atherosclerosis, thrombosis, and hypertension by altering permeability, promoting inflammation, and impairing vasodilation (Siragusa et al., 2021; Jiang et al., 2022).

Endothelial heterogeneity can also be found within the brain. For instance, in the cerebral ventricles, there is a structure called the choroid plexus, which is responsible for secreting cerebrospinal fluid (CSF). This organ consists of epithelial cells and fenestrated endothelial cells, characterized by the presence of diaphragms (Schmidley and Wissig, 1986). In addition to its role in forming the blood-CSF barrier, the choroid plexus has recently gained attention as a potential site for the initial infection of *T. gondii* in the brain (Figueiredo et al., 2022).

Cerebral endothelial cells are part of the blood-brain barrier (BBB) (Poller et al., 2008; Urich et al., 2012), which consists of multiple associated components, such as pericytes and perivascular astrocytes. Together with neurons, oligodendrocytes and microglia, these components form the neurovascular unit (NVU), which maintains a stable neural environment, regulates cerebral blood flow and protects the brain from toxins (Bobot et al., 2020; Nagata et al., 2021).

Brain microvascular endothelium cells (BMECs) are connected by tight junctions, they lack fenestrations, show minimal pinocytic activity, and have high electrical resistance (TEER), selective permeability (Omran et al., 2020; Sun et al., 2022). BMECs regulate nutrient exchange, modulate immune responses, and influence neuroinflammation via cell adhesion molecules (Mugisho et al., 2020). Single-cell RNA sequencing highlights endothelial heterogeneity (Liu et al., 2021). Under some conditions, immortalized human cerebral microvascular endothelial cells (hCMEC/D3) upregulate MHC class II, reflecting immune shifts (Wheway et al., 2013; Lopes Pinheiro et al., 2016).

Different molecules can modulate gene expression in endothelial cells, ranging from proinflammatory molecules, such as prostaglandins (Wilhelms et al., 2014) to extracellular histones (Pérez-Cremades et al., 2017). Some established molecules for endothelial activation are interleukin 1 beta, tumor necrosis factor alpha (TNF- $\alpha$ ) and lipopolysaccharide (Makó et al., 2010; Jiang et al., 2015; Jiang et al., 2016). Molecules such as cytokines (Bautista et al., 2005), soluble proteins (Sasongko et al., 2014), vascular growth factors (Waheed et al., 2016), elements involved in blood clotting (Jiang et al., 2016) and oxidative stress (Couillard et al., 2005) are commonly identified as inflammatory markers (Drenjancevic et al., 2018).

Endothelial changes can be caused by various infectious agents (De Assis et al., 2000; Knight et al., 2005; Debrah et al., 2007; Liu et al., 2010; Calvert et al., 2015). During dengue virus infection, the endothelium produces large concentrations of IL-8 and initiates the apoptosis process (Avirutnan et al., 1998). In human immunodeficiency virus infection, high serum levels of von Willebrand factor and tissue plasminogen activator resulting from endothelial activation are observed (De Larrañaga et al., 2003). Endothelial cells infected by Chlamydia pneumoniae are activated by increased expression of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1), E-selectin and mitogen-activated protein kinase (Krüll et al., 1999). Brain endothelial cells infected by Streptococcus pneumoniae express high levels of IL-8 and the chemokines CXCL-1 and CXCL-2 in response to bacterial neuroaminidases (Banerjee et al., 2010).

It is important to emphasize that, despite their significant role, endothelial cells do not perform their functions alone. For example, the loss or degeneration of pericytes (cells located around blood vessels) disrupts cerebral blood flow, leading to an imbalance in neural function (Nikolakopoulou et al., 2019; Hartmann et al., 2021). Additionally, Menard et al. demonstrated that pericyteendothelial communication plays a crucial role in regulating emotional responses to stress and anxiety, as pericyte ablation resulted in these behaviors (Menard et al., 2024). As a cascade effect, for the endothelium-pericyte interaction to occur, astrocytic end-feet contribute to the maintenance and regulation of pericyte differentiation, while also modulating the expression of endothelial cell tight junction proteins such as claudin-5 (CLDN5) and ZO-1 (Heithoff et al., 2021a; Heithoff et al., 2021b). In addition, to their well-known role in endothelial cell function, pericytes have also been shown to play a part in the immune response. *In vitro* studies have demonstrated that, in response to inflammatory stimuli, pericytes produce reactive oxygen species, modulate phagocytosis, and regulate the expression of  $\alpha$ -smooth muscle actin and ICAM-1 (Pieper et al., 2014).

Thus, the integrity of this neurovascular unit is crucial for proper brain function, and any disruption in this system can lead to diseases, as will be discussed in later sections.

# *Toxoplasma gondii* and the bloodbrain barrier

*T. gondii* is a zoonotic protozoan of the phylum Apicomplexa (Dubey, 2008), discovered in 1908 in *Ctenodactylus gundi*, and it is capable of infecting different mammals, including humans (Sabin and Olitsky, 1937; Dubey et al., 1997; Dubey, 2008). The life cycle involves sexual reproduction in feline enterocytes due to their lack of the enzyme D6D, leading to the accumulation of linoleic acid, which is essential for *T. gondii* reproduction (Davidson and Haggan, 1990; Di Genova et al., 2019).

Felids ingest tissue cysts, which release trophozoites in the intestine. These invade epithelial cells, undergo asexual replication, and form gametocytes, leading to oocyst production. Oocysts are subsequently excreted in feces and sporulate into resistant forms that can persist in the environment for more than a year (Webster, 1994; Lélu et al., 2012; Hehl et al., 2015). Intermediate hosts, such as rodents, sheep, and humans, ingest oocysts, where tachyzoites invade cells, differentiate into bradyzoites, and form cysts, restarting the cycle upon ingestion by cats (Dubey et al., 1997; Dubey, 2007; Moraes Lm de et al., 2011).

Key clinical complications include neurotoxoplasmosis (Carme et al., 2002; Alvarado-Esquivel et al., 2015) and congenital toxoplasmosis (Da Silva et al., 2015; Maldonado et al., 2017). The latter occurs when *T. gondii* crosses the placenta during pregnancy, causing chorioretinitis, intracranial calcification, and hydrocephalus (Maldonado et al., 2017). With up to 80% incidence in endemic areas, diagnosis is challenging owing to nonspecific signs in most cases (Montoya and Remington, 2008; Da Silva et al., 2015). To invade the brain, *T. gondii* must leave the bloodstream and cross the BBB. To overcome this barrier, different mechanisms have been proposed, including those involving paracellular, transcellular and infected immune cells. Different lines of study strongly suggest that *T. gondii* can use all routes (Daneman and Rescigno, 2009; Lachenmaier et al., 2011; Konradt et al., 2016) (Figure 1).

The paracellular route involves the passage of a pathogen through the junctions between endothelial cells. Although *T. gondii* lacks a flagellum for mobility, it moves via actin and

myosin in a process called gliding motility (Dobrowolski and Sibley, 1996). *T. gondii* is capable of overcoming the intestinal epithelium via the paracellular route (Weight and Carding, 2012), and since this epithelium has similarities with the BBB, invasion of the CNS via this route has become plausible. *T. gondii* can also cross the BBB through the transcellular route in a murine model, invading cells and traversing them without promoting significant damage or inducing lysis. Additionally, the parasite can use endothelial cells as a replicative niche (Konradt et al., 2016; Figueiredo et al., 2022).

Leukocytes infected with T. gondii exhibit increased motility and the ability to cross the BBB under static or flowing culture conditions (Lachenmaier et al., 2011; Harker et al., 2013; Ueno et al., 2014). Another study carried out in the pulmonary endothelium revealed a mixture of T. gondii-infected leukocytes via the transcellular route. In this work, the authors observed that T. gondii leaves the host leukocyte once it is close enough to an endothelial cell that would host the protozoan (Baba et al., 2017). Once the parasite reaches the brain, it can invade any nucleated cell. Interestingly, in vitro, the parasite can establish a persistent infection in any of these cells (Fischer et al., 1997). However, in vivo, infection and its maintenance, in the form of cysts, can be observed only in neurons. The most intriguing finding is that studies have shown not only that neurons are unable to resolve infection, similar to other neural cells but also that they are the primary target of infection by this parasite (Cabral et al., 2016). In this context, successful elimination of the parasite relies on the synergistic action of IFN- $\gamma$  and TNF- $\alpha$  produced by immune cells (Scharton-Kersten et al., 1997; Ibrahim et al., 2009). When in contact with the target cell, these inflammatory molecules promote the action of indoleamine-2-3 dioxygenase, iNOS and eNOS (Däubener et al., 2001; Dincel and Atmaca, 2015). Indoleamine-2-3 dioxygenase acts by catabolizing cellular tryptophan and deprives T. gondii of this essential amino acid, which results in elimination of the parasite (Däubener et al., 2001). eNOS activity in endothelial cells promotes the formation of nitrites, anions, superoxides and nitric oxide. These molecules have the potential to inhibit the development of T. gondii in macrophages and fibroblasts when they act together with other harmful agents to the parasite (Woodman et al., 1991). iNOSknockout (iNOS-/-) mice infected with T. gondii presented increased tissue parasitism and an inflammatory reaction in the CNS (Silva et al., 2009). These findings suggest that reactive oxygen species play a neuroprotective role in T. gondii infections. On the other hand, there is evidence that reactive oxygen species triggered by different factors can promote weakening of the BBB (Bao and Shi, 2010) and intensify encephalitis in infected mice (Dincel and Atmaca, 2015). Therefore, reactive oxygen species seem to have an ambiguous effect on neurotoxoplasmosis.

IFN- $\gamma$  influences various cells, leading to the upregulation of iNOS, a pivotal factor in the clearance of intracellular tachyzoites, particularly within the CNS, which is achieved by inhibiting parasitic mitochondrial function (Scharton-Kersten et al., 1997; Ibrahim et al., 2009). The regulatory function of iNOS is facilitated by the production of anti-inflammatory interleukins,



Toxoplasma gondii infection. After trophozoites leave the intestine, they enter the bloodstream (A), where they reach various anatomical sites, including areas with significant neurotropism. In these locations, the parasites are able to cross the blood-brain barrier (B) through mechanisms such as paracellular passage (1B), the Trojan horse mechanism (2B), and transcellular passage (3B). Once inside neurons, the parasites induce several changes, including rerouting of the tryptophan metabolic pathway toward the parasite, which leads to a reduction in serotonin production (C) and an increase in dopamine release (D). Created in BioRender. Albrecht, L. (2024) https://app.biorender.com/citation/673d2af55625e5565695ea24

such as IL-10, by cells such as CD4<sup>+</sup> Foxp3<sup>+</sup> T (Treg) cells, thereby fostering host homeostasis (Oldenhove et al., 2009). Additionally, IFN-y secreted by brain-resident cells enhances the expression of molecules involved in T-cell immunity, such as chemokines (CXCL9, CXCL10 and CXCL11), MHC I and MHC II, ICOSL costimulatory molecules and cytokines, including IL-12, IL5- and IL-18 (Suzuki et al., 2023).

MCP1, also known as CCL-2, is a monocyte chemoattractant (Deshmane et al., 2009). Its production is associated with inflammation, monocytic infiltrates and apoptotic events (Gerszten et al., 1999; Zhang et al., 2011). In the context of endothelium infection, the expression of MCP1 varies according to the infectious agent. MCP1 is upregulated in hepatitis C virus infection (Liu et al., 2016), and its expression is basal in Cryptococcus neoformans infection (Jong et al., 2008). In endothelial cells infected by T. gondii, the expression of MCP1 is maintained for up to 24 hours after the onset of infection (Knight et al., 2005). The parasite surface antigen glycoprotein 1 (SAG1) is sufficient to stimulate MCP1 expression in endothelial cells (Brenier-Pinchart et al., 2006). An imbalance in MCP1 synthesis may be associated with neuroinflammatory processes (Sawyer et al., 2014).

ADAMTS-13 is produced by endothelial cells. Its main function is related to coagulation; however, this molecule has a neuroprotective role by regulating von Willebrand factor activity, preventing microvascular thrombosis and reducing oxidative stress (Fujioka et al., 2010; Khan et al., 2012). High levels of ADAMTS-13 were observed in the brains of T. gondii-infected animals at 10, 30 and 60 days post infection, and a potential neuroprotective role was postulated (Dincel and Atmaca, 2016). The infection of human BMECs by T. gondii is reduced after the use of drugs such as monensin, which interferes with the host cell cycle, DNA synthesis and repair mechanisms (Harun et al., 2020).

Cerebral toxoplasmosis is characterized by the successful infiltration of T. gondii into the CNS. Once situated, tissue cysts containing protozoans in the bradyzoite stage can induce cellular alterations leading to various types of host afflictions (Prandovszky et al., 2011). The presence of cerebral cysts is linked to the recruitment of the complement system protein C1q, which plays a pivotal role in eliminating protozoans (Xiao et al., 2016). However, its presence, particularly in excess, can disrupt neuronal synapses, potentially leading to neurological disorders (Xiao et al., 2016). T. gondii infection triggers the production of antibodies targeting N-methyl-D-aspartate (NMDA), a member of the ligandgated ionotropic glutamate receptor subset, impeding proper synaptic propagation. Glutamate binding to NMDA receptors is vital for synaptic processes, especially learning (Lang et al., 2018; Zhu et al., 2018). This interaction is closely associated with neurological conditions such as Alzheimer's disease and psychotic symptoms (Li et al., 2018), notably schizophrenia and bipolar disorder (Brooks et al., 2015).

*T. gondii* infection in the brain occurs mostly in neurons, leading to alterations in synapses, particularly glutamatergic and GABAergic synapses (Mouveaux et al., 2021). Importantly, GABA is an inhibitory neurotransmitter, and a deficiency in this neurotransmitter can result in various effects, one of which is the occurrence of seizures (Petroff et al., 1996). In addition to disrupting chemical synapses, infection triggers the activation of microglia, which, once activated, contribute to the loss of perisomatic inhibitory synapses via phagocytosis. This provides a potential mechanism for how infection by this pathogen may lead to seizures and psychiatric disorders (Carrillo et al., 2020).

The effects of infection also extend to other types of nerve cells beyond microglia, as shown by the reduction in the glutamate transporter GLT-1 in astrocytes. This leads to an increase in extracellular glutamate, which causes excitotoxicity (excessive activation of glutamate receptors, such as NMDA). This, in turn, generates a calcium overload in the cells, activating several intracellular signaling pathways that damage cellular structures, including reducing the number of dendritic spines. This is one of the mechanisms proposed to explain the dendritic reduction observed after *T. gondii* infection (David et al., 2016).

In addition to the more classic events described above, neurons infected with *T. gondii* cysts also exhibited alterations in cell–cell communication pathways, particularly through extracellular vesicles. Infected neurons showed reduced vesicle production, and their content was altered, containing proteins specific to *T. gondii*, such as GRA1, GRA2, GRA7, MAG1, and MAG2. Considering the intrinsic neuron–astrocyte communication, vesicles from infected neurons could also alter the gene expression of adjacent astrocytes (Tabaie et al., 2024).

These data highlight the significant impact of parasite infection on the brain parenchyma, with many pathways being redirected to support the success and benefit of the parasite. In fact, these chemical and physical changes have sparked discussions about whether they could be the cause of, or contribute to, the behavioral changes observed in rodents (Vyas et al., 2007) and psychiatric conditions, particularly schizophrenia. Recently, double impact theory has been proposed, suggesting early environmental risk. This affects the GABAergic, glutamatergic, or dopaminergic systems (as observed in *T. gondii* infection) and increases susceptibility to other risk factors later in life (theory reviewed by Guerrin et al., 2021).

## Endothelium and schizophrenia

The BBB is a complex structure, and as part of the neurovascular unit, cerebral endothelial cells form a protective

barrier that helps maintain neuronal homeostasis. Dysfunction of the BBB might contribute to the pathogenesis of mental disorders such as depression, bipolar affective disorder, schizophrenia, dementia, intellectual disability and developmental disorders, including autism (World Health Organization, 2022a). These disorders affect approximately 1 in 4 people worldwide (World Health Organization, 2022b), with a combination of abnormal thoughts, perceptions, emotions and behaviors as clinical manifestations. Despite the heterogeneity of symptoms among them, it has been observed that cognitive dysfunction is a common pathway (MacQueen and Memedovich, 2017; Knight et al., 2018; Semkovska et al., 2019; Zhao et al., 2022).

Cognitive dysfunction is related to synaptic dysfunction; however, the adjacent factors that culminate in these events are still undetermined. Many researchers have suggested that inflammation and immune dysfunction can directly or indirectly contribute to neural networks (Deanna et al., 2018; Di Biase et al., 2021; Cui et al., 2023). This hypothesis of the brain–immune system axis was reinforced when an alteration in the permeability of the BBB was reported in mood disorders, autistic spectrum disorders and schizophrenia (Greene et al., 2020). Significant alterations, including basal lamina deformation, cytoplasmic vacuolization in endothelial cells (Uranova et al., 2010), and damage and loss of pericapillary oligodendrocytes in the prefrontal cortex (Vostrikov et al., 2008), has been observed in the postmortem brain of patients with schizophrenia.

In addition to structural dysfunction, the gold standard for assessing BBB permeability is the albumin ratio between CSF and blood. Since albumin levels are normally low in CSF, an increase indicates protein leakage from the blood into the CSF. Elevated CSF albumin levels have been observed in patients with schizophrenia (Bechter et al., 2010; Jeppesen et al., 2022; Campana et al., 2023). BBB permeability has been also observed through structural magnetic resonance imaging (Cheng et al., 2022; Moussiopoulou et al., 2023). This altered permeability facilitates the crossing of peripheral inflammatory factors, such as cytokines, across the CNS, which can trigger or ameliorate neural cell dysfunction. Among the cellular components, increased microglial activity, resulting from either external factors (such as peripheral cytokines) or internal factors (such as CNS infections), is a well-established risk factor for the development of mental illness (reviewed by Lurie, 2018).

In addition to the BBB, structural changes in the choroid plexus epithelium and the vascular endothelium have also been reported in pediatric patients (Zhou et al., 2020). Bitanihirwe et al (2022) reported an increased volume of the choroid plexus in patients with first-episode psychosis. Zeng et al. (2024) reported an enlargement in the choroid plexus of schizophrenia patients. These findings highlight significant morphological changes in patients with schizophrenia, with each component potentially contributing individually or collectively to the symptoms and progression of the disease.

Schizophrenia encompasses a wide range of symptoms, which can be categorized into three main types: positive symptoms (such as hallucinations and delusions), negative symptoms (including blunted affect, avolition, alogia and anhedonia) and cognitive symptoms (such as deficits in learning, memory and executive function) (American Psychiatric Association, 1994).

Schizophrenia patient-derived endothelial cells from induced pluripotent stem cells exhibit increased paracellular permeability in vitro (Stankovic et al., 2024). Among the paracellular mechanisms, tight junctions play a key role. Suppression of CLDN5 is associated with psychosis-like symptoms; deficits in learning, memory and sensorimotor control in mice (Greene et al., 2018); symptoms similar to those found in schizophrenia. These findings suggest that changes in the BBB could be linked to the patient's symptoms. The expression of CLDN5, as measured by immunohistochemistry and quantitative PCR, is decreased in patients with schizophrenia and depression according to postmortem analysis (Greene et al., 2020; Lizano et al., 2022). In addition, high levels of IgA antibodies against CLDN5 have been detected in patients with schizophrenia (Maes et al., 2019), which is strongly suggestive of paracellular barrier disruption. It has not yet been elucidated whether the reduction in CLDN5 expression is the result of a single factor or a combination of factors. The contribution of matrix metalloproteinase-1 (MMP-1) to reducing CLDN5 expression has been reported (Rempe et al., 2018).

Endothelial cells from brain organoids derived from patients with schizophrenia exhibit alterations in angiogenic pathways and cell cycle regulation (Stankovic et al., 2024). Changes were observed in the EIF2, ID1, and mTOR pathways, with particular emphasis on the ID1 pathway, which activates HIF-1a and vascular endothelial growth factor-A (Stankovic et al., 2024).

Vascular endothelial growth factor (VEGF) levels have sparked significant scientific discussion; however, the findings remain conflicting. Pillai et al (2015) reported increased serum levels and VEGF expression in the parietal cortex, whereas Fulzele & Pillai (Fulzele and Pillai, 2009) reported reduced VEGF expression in the dorsolateral prefrontal cortex. Serum VEGF levels were lower in nonremitted first-episode psychosis patients than in remitted patients and healthy controls (Zhao et al., 2019). However, other studies have failed to detect significant differences in VEGF levels between patients with schizophrenia and healthy controls (Nguyen et al., 2018; Pu et al., 2020). An explanation for these differences is directly related to patient condition, since VEGF levels change with the use of antipsychotics. Medication-free patients have decreased serum VEGF levels, which tend to increase with treatment (Lee et al., 2015; Xiao et al., 2018; Xiao et al., 2019). VEGF is produced by different cells, such as astrocytes, neurons, endothelial cells and microglia; therefore, understanding its expression at the brain level would be interesting since it plays a role in modulating the BBB (Proescholdt et al., 1999). VEGF controls the expression of tight junction proteins such as CLND5 and occludin, downregulating their expression, leading to BBB disruption (Argaw et al., 2009) and facilitating the infiltration of peripheral cells into the CNS (Cai et al., 2020a).

The entry of peripheral cells is facilitated by the expression of adhesion molecules, such as selectins, ICAM-1 and VCAM-1. The expression of these adhesive molecules is altered in patients with schizophrenia, depending on the stage of the disease and type of treatment (Cai et al., 2020a). The serum level of soluble ICAM-1

(sICAM-1) is lower in patients before the initiation of antipsychotic therapy than in controls (Schwarz et al., 2000; Krönig et al., 2005; Kavzoglu and Hariri, 2013; Radu et al., 2020). Although Schwarz et al (2000) did not observe a difference in sICAM-1 levels after therapy, several studies have reported an increase in sICAM-1 levels following treatment (Meyer et al., 2009; Kavzoglu and Hariri, 2013; Cai et al., 2020b; Radu et al., 2020). Elevated sICAM-1 levels have been observed in chronic patients receiving continuous medication (Nguyen et al., 2018; Cai et al., 2020a; Sheikh et al., 2023).

The data regarding soluble VCAM (sVCAM) levels in patients with schizophrenia are more conflicting. Kavzoglu & Hariri (Kavzoglu and Hariri, 2013) did not find a difference in plasma sVCAM levels between patients with first-episode psychosis and controls. They reported that, after drug therapy, the levels of this molecule remained at baseline (Kavzoglu and Hariri, 2013). Moreover, Radu et al. (2020) initially detected increased sVCAM levels in patients with schizophrenia, which began to decrease after therapeutic intervention. In contrast, Meyer et al. (2009) did not observe any differences in sVCAM levels between patients receiving antipsychotic therapy and controls.

Stefanović et al. (2016) explored the differences in these adhesion molecules during the different stages of the disease, following the initial phase (period until 3 years after first-episode psychosis) and final phase (minimum of 10 years after the diagnosis of schizophrenia). To minimize interfering variables, only patients who were not on major psychotropic drugs for at least four weeks prior to hospitalization were included. During the initial phase, they detected normal levels of sICAM1 and reduced levels of sVCAM, whereas in the late phase, they reported that the levels of sICAM increased and those of sVCAM decreased (Stefanović et al., 2016). sICAM-1 originates from proteolytic cleavage of membrane ICAM-1 or alternative mRNA ICAM-1 splicing and has a wide tissue distribution (King et al., 1995). Thus, the increase in sICAM-1 provides a general picture of inflammation, whereas the increase in sVCAM is related to endothelial dysfunction (Radu et al., 2020).

Alterations in soluble P-selectin (sP-selectin), a molecule that slows leukocytes on the endothelial surface before they bind tightly to cellular adhesion molecules, was also observed in patients with schizophrenia (Pinjari et al., 2022). Patients with schizophrenia had a positive correlation between sP-selectin levels and the astrocytic marker S100B (Pinjari et al., 2022). S100B is a calcium-binding peptide produced primarily by astrocytes. As its concentration is practically undetectable in healthy individuals, an increase in its level is associated with pathologies that disturb the BBB. Indeed, some studies have detected elevated levels of this marker in the blood, CSF and brain of patients with schizophrenia (Wiesmann et al., 1999; Lara et al., 2001; Schroeter et al., 2003; Kealy et al., 2020).

There is also a positive correlation between sP-selectin and interleukin 6 (IL-6) in patients with schizophrenia (Pinjari et al., 2022). Pillai et al. (2015) reported a positive correlation between increased serum levels of VEGF and IL-6 in patients with schizophrenia. Taken together, these data support the hypothesis that inflammation may be an important contributor to the etiology of schizophrenia (Fan et al., 2007; Potvin et al., 2008; Drexhage et al., 2010).

The upregulation of mRNAs and proteins related to the inflammatory response is found in patients with schizophrenia (Zhu et al., 2022). A subgroup of patients with schizophrenia shows an exaggerated increase in the mRNA levels of inflammatory cytokines, such as IL-1 $\beta$ , IL-6, IL-8 and SERPIN3, in the frontal cortex; these patients are designated high-profile inflammatory patients (Fillman et al., 2013; Zhang et al., 2016). The peripheral cytokine profile is used to classify patients with schizophrenia into high or low inflammatory biotypes (Fillman et al., 2016) (Cai et al., 2020a). Patients with a high inflammatory profile present important neuronal alterations, such as cognitive deficits, a reduction in brain volume (Fillman et al., 2014), and a reduction in cortical gray matter volume (Zhang et al., 2016).

The links among inflammation, cognitive impairments, and brain changes suggest that targeting inflammatory pathways is a promising treatment for schizophrenia, particularly in highinflammatory patients with severe neurological deficits. Inflammation may increase BBB permeability and neuronal function, leading to dysfunction of the neurovascular unit and contributing to disease progression. Additionally, the role of infectious agents in immune dysfunction warrants further study, offering insights into the complex causes of schizophrenia and potential targeted therapies.

# Relationship between schizophrenia, toxoplasmosis and endothelium

Chronic infection by T. gondii results in decreased synaptic density, neural apoptosis, a reduction in dendritic arbor and spine density and abnormalities in neurotransmitters (such as increased dopamine) due to excessive secretion of cytokines from microglia and astrocytes (Parlog et al., 2014; Wang et al., 2019). This is accompanied by increased extracellular glutamate and reduced glutamate transporter activity in glial cells (David et al., 2016). Other synaptosomal proteins, such as EAAT2, Shank3, AMPA and NMDA receptors, are also dysregulated (Lang et al., 2018). These events help in understanding the behavioral changes in the host caused by T. gondii (Barrios et al., 2021). Some of those findings are similar in patients with schizophrenia. Decreased synapse density (Van Berlekom et al., 2020), increased dopamine release (McCutcheon et al., 2019), NMDA hypofunction (Weickert et al., 2013) and apoptosis due to microglial activation (Parellada and Gassó, 2021) are some of the biological findings in schizophrenia. An example of the infection process and the access of T. gondii to neurons and some of its consequences are shown in Figure 1.

Studies carried out around the world reported a higher seroprevalence of anti-*T. gondii* antibodies in populations with schizophrenia than in healthy populations (Cetinkaya et al., 2007; Dogruman-Al et al., 2009; Yuksel et al., 2010; Alipour et al., 2011; Alvarado-Esquivel et al., 2011; Fond et al., 2018; Burgdorf et al., 2019; Morais et al., 2019; Stepanova et al., 2019; Kezai et al., 2020; Ekici et al., 2021; Galván-Ramírez-M-de-la et al., 2021; Grada et al., 2022; Omer, 2022; Lili et al., 2024). The relationship between this pathogen and schizophrenia has been explored, and patients with schizophrenia exhibit a more inflammatory state that can lead to altered permeability of the BBB, and this event can be exacerbated by T. gondii infection (Zhu et al., 2022). In addition to acute infection, the persistence of parasitic cysts in the brain promotes chronic inflammation, which in turn leads to changes in the BBB, facilitating the entry of cytokines from the bloodstream into brain tissue (Barrios et al., 2021). T. gondii seropositivity is linked to increased levels of neuron-specific enolase and IL-18 (Andreou et al., 2024). IL-18 is particularly noteworthy, as it can positively regulate the production of INF- $\gamma$  (Berg et al., 2002). In turn, IFN- $\gamma$ not only is involved in the immune response against the parasite but also promotes an increase in adhesion molecules, such as ICAM-1 (Jahnke and Johnson, 1995), which is also altered in schizophrenia. In this context, Pinjari et al. (2022) reported that sP-selectin is positively correlated with interleukin 6 (IL-6). A study evaluating the function of BMECs revealed an increase in CCL2 in a group exhibiting a BBB deficit, which was observed in a subgroup of patients with SZ or bipolar disorder (BD) (Lizano et al., 2023). CCL2, along with P-selectin, IL-6, TNF-a, CXCL9, MMP-8 and MMP-13, also appears to be deregulated in T. gondii infection (Lachenmaier et al., 2011; Figueiredo et al., 2022).

Although overlapping pathways can be found in these pathologies, it is still undetermined which events occur first. In this context, two scenarios can be defined. First, it could be hypothesized that patients with schizophrenia are more susceptible to infection because they have a greater inflammatory state, with the upregulation of adhesion molecules (ICAM-1, sPselectin) and chemokines (such as CCL2). The importance of ICAM-1 stands out here, as it is the main molecule responsible for the transmigration of immune cells to the brain parenchyma (Cai et al., 2020b). In addition, the neutrophil-lymphocyte ratio in the blood of patients with schizophrenia is elevated (Semiz et al., 2014; Šagud et al., 2023; Liang et al., 2024). Therefore, when these individuals are infected by T. gondii, not only are greater quantities of cells available for the parasite to infect but also the chances of parasitized cells (in the Trojan horse strategy: see Figure 1) entering the brain are greater. Once infection is established in the nervous system, it can exacerbate the neuroinflammation observed in patients with schizophrenia (Doorduin et al., 2009).

The second scenario suggests that the infection occurred prior to the outcome of schizophrenia (Niebuhr et al., 2008; Sutterland et al., 2015). In this context, parasite infection leads to the production of antibodies, and since peptide overlap exists between *T. gondii* and the NMDA receptor subunits, it could lead to a cross-reaction between anti-*T. gondii* antibodies and NMDA receptor subunits (Lucchese, 2017), resulting in NDMA receptor dysfunction. In fact, one of the arms that seeks to explain the etiology of schizophrenia is dysfunction of this same receptor (Northoff et al., 2005). In addition, after activation by IFN- $\gamma$ , astrocytes and microglia become the main effector cells in defense against the parasite via the secretion of IL-1, IL-6, GM-CSF or IL-10 and TNF- $\alpha$ , respectively (Maenz et al., 2014). TNF- $\alpha$  and IL-6 are associated with an increase in MMP-1 (Du et al., 2016). This can activate other MMPs, such as MMP-2 and MMP-9, which can reduce the expression of tight junction proteins associated with BBB disruption (Rempe et al., 2018). In addition, individuals with schizophrenia have high levels of MMP-9 (Domenici et al., 2010; Yamamori et al., 2013; Devanarayanan et al., 2016; Ali et al., 2017).

Therefore, inflammatory processes, as discussed in the previous paragraph, may help explain the existence of a subgroup of patients with schizophrenia who have altered BBB permeability (Najjar et al., 2017; Cai et al., 2020a; Hoang et al., 2022), as well as subtypes of patients with a greater inflammatory state (Bechter et al., 2010; Kunz et al., 2011; Fillman et al., 2013; Fillman et al., 2016). Chronic infection contributes to the establishment of constant neuroinflammation that can impair CNS homeostasis (de Medeiros Brito et al., 2020; Meurer Y da et al., 2020; Brito Rm de et al., 2023). A brief summary of the changes identified in individuals infected with *T. gondii* compared with individuals with schizophrenia is shown in Figure 2. On the basis of these findings, the potential for *T. gondii* infection to trigger neuroinflammation and disrupt NMDA receptor function raises the possibility that infection could contribute to the development of schizophrenia or exacerbate preexisting conditions. Furthermore, the overlap between *T. gondii* antigens and NMDA receptor subunits, leading to a cross-reaction of antibodies, could provide insight into the mechanisms underlying NMDA receptor dysfunction in schizophrenia. These findings highlight the need for further research into the interaction between *T. gondii* and schizophrenia, particularly in exploring whether the infection acts as a trigger or an exacerbating factor. Such research could suggest therapeutic strategies aimed at modulating neuroinflammation and restoring BBB integrity in affected individuals.

## Perspectives

This review aimed to investigate the interaction between toxoplasmosis and schizophrenia, exploring the factors contributing to the variability in clinical outcomes observed in patients with schizophrenia. By highlighting these discrepancies, we sought to guide the design of future studies by considering variables



#### FIGURE 2

Main activities or molecules altered in toxoplasmosis and schizophrenia. The red boxes represent activities or molecules with increased concentration or activity, whereas the blue boxes represent molecules or activities with reduced concentration or activity. The terms highlighted in bold represent activities or molecules with similar increases or reductions in both toxoplasmosis and schizophrenia. References have been omitted from this figure to facilitate visualization. \*Increase or decrease in the number of molecules according to different studies. Created in BioRender. Albrecht, L. (2024). https://BioRender.com/g51d357.

such as medication, patient age, and the presence or absence of infectious diseases. Given the multifaceted nature of psychiatric disorders, our goal was to contribute to the understanding of the complex puzzle by examining the associations among T. gondii infection, endothelial interactions, and the immune system.

## Author contributions

VC: Conceptualization, Investigation, Writing – original draft. LC: Conceptualization, Investigation, Writing – original draft. RM: Supervision, Writing – review & editing. LA: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

#### Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by ICC-PEP-FIOCRUZ (Grant: ICC-008-FIO-21-2-15). VC and LC received PhD scholarships from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

### **Acknowledgments**

We acknowledge the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for the PhD schoolarships to VCC and LFCG.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### References

Ali, F. T., Abd-El-Azeem, E. M., Hamed, M. A., Ali, M. A. M., Abd-Al-Kader, N. M., and Hassan, E. A. (2017). Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications. *Schizophr. Res.* 188, 98–109. doi: 10.1016/j.schres.2017.01.016

Alipour, A., Shojaee, S., Mohebali, M., Tehranidoost, M., Abdi Masoleh, F., and Keshavarz, H. (2011). Toxoplasma infection in schizophrenia patients: A comparative study with control group. *Iran J. Parasitol.* 6, 31–37.

Alvarado-Esquivel, C., Sánchez-Anguiano, L. F., Mendoza-Larios, A., Hernández-Tinoco, J., Pérez-Ochoa, J. F., Antuna-Salcido, E. I., et al. (2015). Prevalence of *Toxoplasma gondii* infection in brain and heart by immunohistochemistry in a hospital-based autopsy series in Durango, Mexico. *Eur. J. Microbiol. Immunol.* 5, 143–149. doi: 10.1556/1886.2015.00014

Alvarado-Esquivel, C., Urbina-Álvarez, J. D., Estrada-Martínez, S., Torres-Castorena, A., Molotla-de-León, G., Liesenfeld, O., et al. (2011). *Toxoplasma gondii* infection and schizophrenia: A case control study in a low Toxoplasma seroprevalence Mexican population. *Parasitol. Int.* 60, 151–155. doi: 10.1016/j.parint.2010.12.003

American Psychiatric Association (1994). *Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). 4th ed* Vol. 29 (Washington, DC: American Psychiatric Association), 529–535 p.

Andreou, D., Steen, N. E., Mørch-Johnsen, L., Jørgensen, K. N., Wortinger, L. A., Barth, C., et al. (2024). *Toxoplasma gondii* infection associated with inflammasome activation and neuronal injury. *Sci. Rep.* 14, 1–9. doi: 10.1038/s41598-024-55887-9

Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., and John, G. R. (2009). VEGFmediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc. Natl. Acad. Sci. U S A.* 106, 1977–1982. doi: 10.1073/pnas.0808698106

Avirutnan, P., Malasit, P., Seliger, B., Bhakdi, S., and Husmann, M. (1998). Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. *J. Immunol.* 161, 6338–6346. doi: 10.4049/jimmunol.161.11.6338

Baba, M., Batanova, T., Kitoh, K., and Takashima, Y. (2017). Adhesion of *Toxoplasma gondii* tachyzoite-infected vehicle leukocytes to capillary endothelial cells triggers timely parasite egression. *Sci. Rep.* 7, 1–9. doi: 10.1038/s41598-017-05956-z

Banerjee, A., van Sorge, N. M., Sheen, T. R., Uchiyama, S., Mitchell, T. J., and Doran, K. S. (2010). Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization. *Cell Microbiol.* 12, 1576–1588. doi: 10.1111/j.1462-5822.2010.01490.x

Bao, L., and Shi, H. (2010). Arsenite induces endothelial cell permeability increase through a reactive oxygen species-vascular endothelial growth factor pathway. *Chem. Res. Toxicol.* 23, 1726–1734. doi: 10.1021/tx100191t

Barrios, L. C., da Silva Pinheiro, A. P., Gibaldi, D., Silva, A. A., Rodrigues e Silva, P. M., Roffè, E., et al. (2021). Behavioral alterations in long-term Toxoplasma gondii infection of C57BL/6 mice are associated with neuroinflammation and disruption of the blood brain barrier. *PLoS One* 16, 1–30. doi: 10.1371/journal.pone.0258199

Bautista, L. E., Vera, L. M., Arenas, I. A., and Gamarra, G. (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- a) and essential hypertension. *J. Hum. Hypertens.* 19, 149–154. doi: 10.1038/ sj.jhh.1001785

Bechter, K., Reiber, H., Herzog, S., Fuchs, D., Tumani, H., and Maxeiner, H. G. (2010). Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction. J. Psychiatr. Res. 44, 321–330. doi: 10.1016/j.jpsychires.2009.08.008

Berg, R. E., Cordes, C. J., and Forman, J. (2002). Contribution of CD8+ T cells to innate immunity: IFN-γ secretion induced by IL-12 and IL-18. *Eur. J. Immunol.* 32, 2807–2816. doi: 10.1002/1521-4141(2002010)32:10<2807::aid-immu2807>3.0.co;2-0

Bitanihirwe, B. K. Y., Lizano, P., and Woo, T. U. W. (2022). Deconstructing the functional neuroanatomy of the choroid plexus: an ontogenetic perspective for studying neurodevelopmental and neuropsychiatric disorders. *Mol. Psychiatry* 27, 3573–3582. doi: 10.1038/s41380-022-01623-6

Bobot, M., Thomas, L., Moyon, A., Fernandez, S., McKay, N., Balasse, L., et al. (2020). Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. *J. Am. Soc. Nephrol.* 31, 1509–1521. doi: 10.1681/asn.2019070728

Bossi, P., Caumes, E., Paris, L., Dardé, M. L., and Bricaire, F. (1998). *Toxoplasma gondii*-associated Guillain-Barre syndrome in an immunocompetent patient. J. Clin. Microbiol. 36, 3724–3725. doi: 10.1128/jcm.36.12.3724-3725.1998

Brenier-Pinchart, M. P., Villena, I., Mercier, C., Durand, F., Simon, J., Cesbron-Delauw, M. F., et al. (2006). The Toxoplasma surface protein SAG1 triggers efficient *in vitro* secretion of chemokine ligand 2 (CCL2) from human fibroblasts. *Microbes Infect.* 8, 254–261. doi: 10.1016/j.micinf.2005.06.023

Brito Rm de, M., da Silva, M. C. M., Vieira-Santos, F., de Almeida Lopes, C., Souza, J. L. N., Bastilho, A. L., et al. (2023). Chronic infection by atypical Toxoplasma gondii strain induces disturbance in microglia population and altered behaviour in mice. *Brain Behav. Immun. - Heal.* 30. doi: 10.1016/j.bbih.2023.100652

Brooks, J. M., Carrillo, G. L., Su, J., Lindsay, D. S., Fox, M. A., and Blader, I. J. (2015). *Toxoplasma gondii*Infections alter GABAergic synapses and signaling in the central nervous system. *MBio.* 6, e01428–e01415. doi: 10.1128/mbio.01428-15

Burgdorf, K. S., Trabjerg, B. B., Pedersen, M. G., Nissen, J., Banasik, K., Pedersen, O. B., et al. (2019). Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. *Brain Behav. Immun.* 79, 152–158. doi: 10.1016/j.bbi.2019.01.026

Cabral, C. M., Tuladhar, S., Dietrich, H. K., Nguyen, E., MacDonald, W. R., Trivedi, T., et al. (2016). Neurons are the primary target cell for the brain-tropic intracellular parasite *toxoplasma gondii*. *PLoS Pathog.* 12, 1–20. doi: 10.1371/journal.ppat.1005447

Cai, H. Q., Catts, V. S., Webster, M. J., Galletly, C., Liu, D., O'Donnell, M., et al. (2020a). Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. *Mol. Psychiatry* 25, 761–775. doi: 10.1038/s41380-018-0235-x

Cai, H. Q., Weickert, T. W., Catts, V. S., Balzan, R., Galletly, C., Liu, D., et al. (2020b). Altered levels of immune cell adhesion molecules are associated with memory impairment in schizophrenia and healthy controls. *Brain Behav. Immun.* 89, 200– 208. doi: 10.1016/j.bbi.2020.06.017

Calvert, J. K., Helbig, K. J., Dimasi, D., Cockshell, M., Beard, M. R., Pitson, S. M., et al. (2015). Dengue virus infection of primary endothelial cells in endothelial cells function and is restricted by interferon-stimulated responses. *J. Interf Cytokine Res.* 35, 1–12. doi: 10.1089/jir.2014.0195

Campana, M., Löhrs, L., Strauß, J., Münz, S., Oviedo-Salcedo, T., Fernando, P., et al. (2023). Blood-brain barrier dysfunction and folate and vitamin B12 levels in firstepisode schizophrenia-spectrum psychosis: a retrospective chart review. *Eur. Arch. Psychiatry Clin. Neurosci.* 273, 1693–1701. doi: 10.1007/s00406-023-01572-3

Carme, B., Bissuel, F., Ajzenberg, D., Bouyne, R., Aznar, C., Demar, M., et al. (2002). Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J. Clin. Microbiol. 40, 4037–4044. doi: 10.1128/jcm.40.11.4037-4044.2002

Carrillo, G. L., Ballard, V. A., Glausen, T., Boone, Z., Teamer, J., Hinkson, C. L., et al. (2020). Toxoplasma infection induces microglia-neuron contact and the loss of perisomatic inhibitory synapses. *Glia.* 68, 1968–1986. doi: 10.1002/glia.23816

Catts, V. S., Wong, J., Fillman, S. G., Fung, S. J., and Shannon Weickert, C. (2014). Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation. *Aust. N Z J. Psychiatry* 48, 722–734. doi: 10.1177/ 0004867414531078

Cetinkaya, Z., Yazar, S., Gecici, O., and Namli, M. N. (2007). Anti-*Toxoplasma gondii* antibodies in patients with schizophrenia - Preliminary findings in a Turkish sample. *Schizophr. Bull.* 33, 789–791. doi: 10.1093/schbul/sbm021

Cheng, Y., Wang, T., Zhang, T., Yi, S., Zhao, S., Li, N., et al. (2022). Increased bloodbrain barrier permeability of the thalamus correlated with symptom severity and brain volume alterations in patients with schizophrenia. *Biol. Psychiatry Cognit. Neurosci. Neuroimaging.* 7, 1025–1034. doi: 10.1016/j.bpsc.2022.06.006

Couillard, C., Ruel, G., Archer, W. R., Pomerleau, S., Bergeron, J., Couture, P., et al. (2005). Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. *J. Clin. Endocrinol. Metab.* 90, 6454–6459. doi: 10.1210/jc.2004-2438

Cui, L. B., Wang, X. Y., Fu, Y. F., Liu, X. F., Wei, Y., Zhao, S. W., et al. (2023). Transcriptional level of inflammation markers associates with short-term brain structural changes in first-episode schizophrenia. *BMC Med.* 21, 1–13. doi: 10.1186/ s12916-023-02963-y

Daneman, R., and Rescigno, M. (2009). The gut immune barrier and the blood-brain barrier: are they so different? *Immunity*. 31, 722-735. doi: 10.1016/j.immuni.2009.09.012

Da Silva, M. G., Vinaud, M. C., and De Castro, A. M. (2015). Prevalence of toxoplasmosis in pregnant women and vertical transmission of *Toxoplasma gondii* in patients from basic units of health from Gurupi, Tocantins, Brazil, from 2012 to 2014. *PLoS One* 10, 1–15. doi: 10.1371/journal.pone.0141700

Däubener, W., Spors, B., Hucke, C., Adam, R., Stins, M., Kim, K. S., et al. (2001). Restriction of *Toxoplasma gondii* growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. *Infect. Immun.* 69, 6527–6531. doi: 10.1128/iai.69.10.6527-6531.2001

David, C. N., Frias, E. S., Szu, J. I., Vieira, P. A., Hubbard, J. A., Lovelace, J., et al. (2016). GLT-1-dependent disruption of CNS glutamate homeostasis and neuronal function by the protozoan parasite *toxoplasma gondii*. *PLoS Pathog.* 12, 1–29. doi: 10.1371/journal.ppat.1005643

Davidson, B. C., and Haggan, J. (1990). Dietary polyenoic fatty acids change the response of cat blood platelets to inductions of aggregation by ADP. *Prostaglandins Leukot. Essent. Fat Acids* 39, 31–37. doi: 10.1016/0952-3278(90)90168-k

Deanna, L. K., Haley, K. D., William, W. E., Nicola, C., Jessica, J., Alessio, F., et al. (2018). Anti gliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. *Brain Behav. Immun.* 69, 57–59. doi: 10.1016/j.bbi.2017.10.020

De Assis, M. C., Da Costa, A. O., Barja-Fidalgo, T. C., and Plotkowski, M. C. (2000). Human endothelial cells are activated by interferon- $\gamma$  plus tumour necrosis factor- $\alpha$  to kill intracellular Pseudomonas aeruginosa. *Immunology.* 101, 271–278. doi: 10.1046/j.1365-2567.2000.00102.x

Debrah, A. Y., Mand, S., Toliat, M. R., Marfo-Debrekyei, Y., Batsa, L., Nürnberg, P., et al. (2007). Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A

gene polymorphism are associated with hydrocele development in lymphatic filariasis. *Am. J. Trop. Med. Hyg.* 77, 601–608. doi: 10.4269/ajtmh.2007.77.601

De Larrañaga, G. F., Petroni, A., Deluchi, G., Alonso, B. S., and Benetucci, J. A. (2003). Viral load and disease progression as responsible for endothelial activation and/ or injury in human immunodeficiency virus-1-infected patients. *Blood Coagul Fibrinolysis.* 14, 15–18. doi: 10.1097/00001721-200301000-00004

de Medeiros Brito, R. M., da Silva Rodrigues Meurer, Y., da Silva Santos, L., de Melo Marcelino, B. M., and de-Andrade-Neto, V. F. (2020). Chronic *Toxoplasma gondii* infection contributes to decreasing of perineuronal nets surrounding neurons in the Corpus striatum of mice. *Parasitol. Res.* 119, 1989–1995. doi: 10.1007/s00436-020-06674-8

Deshmane, S. L., Kremlev, S., Amini, S., and Sawaya, B. E. (2009). Monocyte chemoattractant protein-1 (MCP-1): An overview. *J. Interf Cytokine Res.* 29, 313–325. doi: 10.1089/jir.2008.0027

Devanarayanan, S., Nandeesha, H., Kattimani, S., and Sarkar, S. (2016). Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: A case control study. *Clin. Chem. Lab. Med.* 54, 447–452. doi: 10.1515/cclm-2015-0212

Di Biase, M. A., Zalesky, A., Cetin-Karayumak, S., Rathi, Y., Lv, J., Boerrigter, D., et al. (2021). Large-scale evidence for an association between peripheral inflammation and white matter free water in schizophrenia and healthy individuals. *Schizophr. Bull.* 47, 542–551. doi: 10.1093/schbul/sbaa134

Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Katsafanas, E., Khushalani, S., et al. (2014). Antibodies to *Toxoplasma gondii* in individuals with mania. *Bipolar Disord*. 16, 129–136. doi: 10.1111/bdi.12123

Di Genova, B. M., Wilson, S. K., Dubey, J. P., and Knoll, L. J. (2019). Intestinal delta-6-desaturase activity determines host range for Toxoplasma sexual reproduction. *PLoS Biol.* 17, 1–19. doi: 10.1371/journal.pbio.3000364

Dincel, G. C., and Atmaca, H. T. (2015). Nitric oxide production increases during *Toxoplasma gondii* encephalitis in mice. *Exp. Parasitol.* 156, 104–112. doi: 10.1016/ j.exppara.2015.06.009

Dincel, G. C., and Atmaca, H. T. (2016). Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during *Toxoplasma gondii* encephalitis in mice. *Neuropathology*. 36, 211–226. doi: 10.1111/neup.12263

Dobrowolski, J. M., and Sibley, L. D. (1996). Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. *Cell.* 84, 933–939. doi: 10.1016/s0092-8674(00)81071-5

Dogruman-Al, F., Aslan, S., Yalcin, S., Kustimur, S., and Turk, S. (2009). A possible relationship between *Toxoplasma gondii* and schizophrenia: A seroprevalence study. *Int. J. Psychiatry Clin. Pract.* 13, 82–87. doi: 10.1080/13651500802624738

Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., et al. (2010). Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. *PLoS One* 5. doi: 10.1371/journal.pone.0009166

Doorduin, J., De Vries, E. F. J., Willemsen, A. T. M., De Groot, J. C., Dierckx, R. A., and Klein, H. C. (2009). Neuroinflammation in schizophrenia-related psychosis: A PET study. *J. Nucl. Med.* 50, 1801–1807. doi: 10.2967/jnumed.109.066647

Drenjancevic, I., Jukic, I., Stupin, A., Cosic, A., Marko, S., and Selthofer-Relatic, K. (2018). The Markers of Endothelial Activation, Endothelial Dysfunction - Old Concepts and New Challenges (IntechOpen), 391–417. doi: 10.5772/intechopen.68656

Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L., Beumer, W., Versnel, M. A., et al. (2010). The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. *Expert Rev. Neurother.* 10, 59–76. doi: 10.1586/ern.09.144

Du, G., Liu, C., Li, X., Chen, W., He, R., Wang, X., et al. (2016). Induction of matrix metalloproteinase-1 by tumor necrosis factor- $\alpha$  is mediated by interleukin-6 in cultured fibroblasts of keratoconus. *Exp. Biol. Med.* 241, 2033–2041. doi: 10.1177/1535370216650940

Dubey, J. (2007). Bradyzoite-induced murine toxoplasmosis: stage conversion, pathogenesis, and tissue cyst formation in mice fed bradyzoites of - different strains of. *Toxoplasma gondii. J. Eukaryot Microbiol.* 44, 592–602. doi: 10.1111/j.1550-7408.1997.tb05965.x

Dubey, J. P. (2008). The history of toxoplasma gondii —The first 100 years. J. Eukaryot Microbiol. 55, 467–475. doi: 10.1111/j.1550-7408.2008.00345.x

Dubey, J. P., Speer, C. A., Shen, S. K., Kwok, O. C. H., and Blixt, J. A. (1997). Oocystinduced murine toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed *toxoplasma gondii* oocysts. *J. Parasitol.* 83, 870. doi: 10.2307/3284282

Ekici, A., Timuçin, D., Gürbüz, E., Ünlü, A., Aydemir, S., and Yilmaz, H. (2021). Investigation of the relationship between schizophrenia and toxoplasmosis in Van province, Turkey. *Parasitol. United J.* 14, 34–38. doi: 10.21608/puj.2021.49914.1093

Fan, X., Goff, D. C., and Henderson, D. C. (2007). Inflammation and schizophrenia. *Expert Rev. Neurother.* 7, 789–796. doi: 10.1586/14737175.7.7.789

Figueiredo, C. A., Steffen, J., Morton, L., Arumugam, S., Liesenfeld, O., Deli, M. A., et al. (2022). Immune response and pathogen invasion at the choroid plexus in the onset of cerebral toxoplasmosis. *J. Neuroinflammation*. 19, 1–18. doi: 10.1186/s12974-021-02370-1

Fillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., Mccrossin, T., et al. (2013). Increased inflammatory markers identified in the dorsolateral prefrontal cortex

of individuals with schizophrenia. Mol. Psychiatry 18, 206-214. doi: 10.1038/mp.2012.110

Fillman, S. G., Weickert, T. W., Lenroot, R. K., Catts, S. V., Bruggemann, J. M., Catts, V. S., et al. (2016). Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume. *Mol. Psychiatry* 21, 1090–1098. doi: 10.1038/mp.2015.90

Fischer, H. G., Nitzgen, B., Reichmann, G., Groß, U., and Hadding, U. (1997). Host cells of *Toxoplasma gondii* encystation in infected primary culture from mouse brain. *Parasitol. Res.* 83, 637–641. doi: 10.1007/s004360050311

Fond, G., Boyer, L., Schürhoff, F., Berna, F., Godin, O., Bulzacka, E., et al. (2018). Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. *Schizophr. Res.* 201, 373–380. doi: 10.1016/j.schres.2018.05.007

Fujioka, M., Hayakawa, K., Mishima, K., Kunizawa, A., Irie, K., Higuchi, S., et al. (2010). ADAMTS13 gene deletion aggravates ischemic brain damage: A possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. *Blood.* 115, 1650–1653. doi: 10.1182/blood-2009-06-230110

Fulzele, S., and Pillai, A. (2009). Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. *Schizophr. Res.* 115, 372–373. doi: 10.1016/j.schres.2009.06.005

Galván-Ramírez-M-de-la, L., Navarro Machuca, G., Covarrubias Castillo, S. A., Benavides González, J. C., Rodríguez Pérez, L. R., Dueñas Jiménez, S. H., et al. (2021). Toxoplasmosis is more frequent in schizophrenia patients than in the general population in Mexico and is not associated with more severe course of schizophrenia measured with the brief psychiatric rating scale. *Pathogens*. 10, 1–8. doi: 10.3390/ pathogens10070820

Gerszten, R. E., Garcia-Zepeda, E. A., Lim, Y. C., Yoshida, M., Ding, H. A., Gimbrone, M. A. Jr, et al. (1999). MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nat.* 398, 718–723. doi: 10.1038/19546

Grada, S., Mihu, A. G., Petrescu, C., Suciu, O., Marincu, I., Lupu, M. A., et al. (2022). *Toxoplasma gondii* infection in patients with psychiatric disorders from Western Romania. *Med.* 58, 1–7. doi: 10.3390/medicina58020208

Greene, C., Hanley, N., and Campbell, M. (2020). Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. *Transl. Psychiatry* 10. doi: 10.1038/s41398-020-01054-3

Greene, C., Kealy, J., Humphries, M. M., Gong, Y., Hou, J., Hudson, N., et al. (2018). Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. *Mol. Psychiatry* 23, 2156–2166. doi: 10.1038/mp.2017.156

Guerrin, C. G. J., Doorduin, J., Sommer, I. E., and de Vries, E. F. J. (2021). The dual hit hypothesis of schizophrenia: Evidence from animal models. *Neurosci. Biobehav. Rev.* 131, 1150–1168. doi: 10.1016/j.neubiorev.2021.10.025

Harker, K. S., Ueno, N., Wang, T., Bonhomme, C., Liu, W., and Lodoen, M. B. (2013). *Toxoplasma gondii* modulates the dynamics of human monocyte adhesion to vascular endothelium under fluidic shear stress. *J. Leukoc. Biol.* 93, 789–800. doi: 10.1189/ jlb.1012517

Hartmann, D. A., Berthiaume, A. A., Grant, R. I., Harrill, S. A., Koski, T., Tieu, T., et al. (2021). Brain capillary pericytes exert a substantial but slow influence on blood flow. *Nat. Neurosci.* 24, 633–645. doi: 10.1038/s41593-020-00793-2

Harun, M. S. R., Taylor, M., Zhu, X. Q., and Elsheikha, H. M. (2020). Transcriptome profiling of Toxoplasma gondii-infected human cerebromicrovascular endothelial cell response to treatment with monensin. *Microorganisms*. 8. doi: 10.3390/microorganisms8060842

Hehl, A. B., Basso, W. U., Lippuner, C., Ramakrishnan, C., Okoniewski, M., Walker, R. A., et al. (2015). Asexual expansion of *Toxoplasma gondii* merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. *BMC Genomics* 16, 1–16. doi: 10.1186/s12864-015-1225-x

Heithoff, B. P., George, K. K., Phares, A. N., Zuidhoek, I. A., Munoz-Ballester, C., and Robel, S. (2021a). Astrocytes are necessary for blood–brain barrier maintenance in the adult mouse brain. *Glia.* 69, 436–472. doi: 10.1002/glia.23908

Heithoff, B. P., George, K. K., Phares, A. N., Zuidhoek, I. A., Munoz-Ballester, C., and Robel, S. (2021b). Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. *Glia.* 69, 436–472. doi: 10.1002/glia.23908

Hoang, D., Xu, Y., Lutz, O., Bannai, D., Zeng, V., Bishop, J. R., et al. (2022). Inflammatory subtypes in antipsychotic-naïve first-episode schizophrenia are associated with altered brain morphology and topological organization. *Brain Behav. Immun.* 100, 297–308. doi: 10.1016/j.bbi.2021.11.019

Ibrahim, H. M., Bannai, H., Xuan, X., and Nishikawa, Y. (2009). *Toxoplasma gondii* cyclophilin 18-mediated production of nitric oxide induces bradyzoite conversion in a CCR5-dependent manner. *Infect. Immun.* 77, 3686–3695. doi: 10.1128/iai.00361-09

Iwabayashi, M., Taniyama, Y., Sanada, F., Azuma, J., and Iekushi, K. (2012). Role of serotonin in angiogenesis : Induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice. *Atherosclerosis*. 220, 337–342. doi: 10.1016/j.atherosclerosis.2011.10.042

Jahnke, A., and Johnson, J. P. (1995). Intercellular adhesion molecule 1 (ICAM-1) is synergistically activated by TNF- $\alpha$  and IFN- $\gamma$  Responsive sites. *Immunobiology*. 193, 305–314. doi: 10.1016/s0171-2985(11)80559-0

Jeppesen, R., Orlovska-Waast, S., Sørensen, N. V., Christensen, R. H. B., and Benros, M. E. (2022). Cerebrospinal fluid and blood biomarkers of neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls. *Schizophr. Bull.* 48, 1206–1216. doi: 10.1093/schbul/sbac098

Jiang, C., Fang, X., Jiang, Y., Shen, F., Hu, Z., Li, X., et al. (2016). TNF- $\alpha$  induces vascular endothelial cells apoptosis through overexpressing pregnancy induced noncoding RNA in Kawasaki disease model. *Int. J. Biochem. Cell Biol.* 72, 118–124. doi: 10.1016/j.biocel.2016.01.011

Jiang, Y., Jiang, L. L. I., Maimaitirexiati, X. M. Z. Y., Zhang, Y., and Wu, L. (2015). Irbesartan attenuates TNF- $\alpha$ -induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF- $\kappa$  B pathway in HUVECs. *Eur. Rev. Med. Pharmacol. Sci.* 19, 3295–3302.

Jiang, L., Lin, L., Li, R., Yuan, C., Xu, M., and Huang, J. H. (2016). conformation of soluble PECAM-1, an endothelial marker. *Int. J. Biochem. Cell Biol.* 77, 102–108. doi: 10.1016/j.biocel.2016.06.001

Jiang, H., Zhou, Y., Nabavi, S. M., Sahebkar, A., Little, P. J., Xu, S., et al. (2022). Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis. *Front. Cardiovasc. Med.* 9, 1–11. doi: 10.3389/ fcvm.2022.925923

Jong, A., Wu, C. H., Zhou, W., Chen, H. M., and Huang, S. H. (2008). Infectomic analysis of gene expression profiles of human brain microvascular endothelial cells infected with cryptococcus neoformans. *J. BioMed. Biotechnol.* 2008, 7. doi: 10.1155/ 2008/375620

Kavzoglu, S. O., and Hariri, A. G. (2013). Intracellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1) and E-selectin levels in first episode schizophrenic patients. *Klin Psikofarmakol Bülteni-Bulletin Clin. Psychopharmacol.* 23, 205–214. doi: 10.5455/bcp.20130713091100

Kealy, J., Greene, C., and Campbell, M. (2020). Blood-brain barrier regulation in psychiatric disorders. *Neurosci. Lett.* 726. doi: 10.1016/j.neulet.2018.06.033

Kezai, A. M., Lecoeur, C., Hot, D., BouneChada, M., Alouani, M. L., and Marion, S. (2020). Association between schizophrenia and Toxoplasma gondii infection in Algeria. *Psychiatry Res.* 291. doi: 10.1016/j.psychres.2020.113293

Khalid, S., Memon, S. F., Jumani, L., Memon, S. A., and Siddiqui, M. S. (2023). Neurotoxoplasmosis in the immunocompetent: A rare occurrence. *Cureus.* 15. doi: 10.7759/cureus.36782

Khan, M. M., Motto, D. G., Lentz, S. R., and Chauhan, A. K. (2012). ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. *J. Thromb. Haemost.* 10, 1665–1671. doi: 10.1111/j.1538-7836.2012.04822.x

King, P. D., Sandberg, E. T., Selvakumar, A., Fang, P., Beaudet, A. L., and Dupont, B. (1995). Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. *J. Immunol.* 154, 6080–6093. doi: 10.4049/jimmunol.154.11.6080

Knight, M. J., Air, T., and Baune, B. T. (2018). The role of cognitive impairment in psychosocial functioning in remitted depression. J. Affect. Disord. 235, 129–134. doi: 10.1016/j.jad.2018.04.051

Knight, B. C., Brunton, C. L., Modi, N. C., Wallace, G. R., and Stanford, M. R. (2005). The effect of Toxoplasma gondii infection on expression of chemokines by rat retinal vascular endothelial cells. *J. Neuroimmunol.* 160, 41–47. doi: 10.1016/jineuroim.2004.10.023

Konradt, C., Ueno, N., Christian, D. A., Delong, J. H., Pritchard, G. H., Herz, J., et al. (2016). Endothelial cells are a replicative niche for entry of *Toxoplasma gondii* to the central nervous system. *Nat. Microbiol.* 1, 1–8. doi: 10.1038/nmicrobiol.2016.1

Krönig, H., Riedel, M., Schwarz, M. J., Strassnig, M., Möller, H. J., Ackenheil, M., et al. (2005). ICAM G241A polymorphism and soluble ICAM-1 serum levels: Evidence for an active immune process in schizophrenia. *Neuroimmunomodulation*. 12, 54–59. doi: 10.1159/000082364

Krüll, M., Klucken, A. C., Fuhrmann, O., Magerl, C., Seybold, J., Hippenstiel, S., et al. (1999). Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. *J. Immunol.* 162, 4834–4841. doi: 10.4049/jimmunol.162.8.4834

Kunz, M., Ceresér, K. M., Goi, P. D., Fries, G. R., Teixeira, A. L., Fernandes, B. S., et al. (2011). Serum levels of IL-6, IL-10 and TNF- $\alpha$  in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. *Rev. Bras. Psiquiatr.* 33, 268–274. doi: 10.1590/s1516-44462011000300010

Lachenmaier, S. M., Deli, M. A., Meissner, M., and Liesenfeld, O. (2011). Intracellular transport of Toxoplasma gondii through the blood-brain barrier. *J. Neuroimmunol.* 232, 119–130. doi: 10.1016/j.jneuroim.2010.10.029

Lang, D., Schott, B. H., van Ham, M., Morton, L., Kulikovskaja, L., Herrera-Molina, R., et al. (2018). Chronic Toxoplasma infection is associated with distinct alterations in the synaptic protein composition. *J. Neuroinflammation.* 15, 1–19. doi: 10.1186/s12974-018-1242-1

Lara, D. R., Gama, C. S., Belmonte-De-Abreu, P., Portela, L. V. C., Gonçalves, C. A., Fonseca, M., et al. (2001). Increased serum S100B protein in schizophrenia: A study in medication-free patients. *J. Psychiatr. Res.* 35, 11–14. doi: 10.1016/s0022-3956(01) 00003-6

Lee, B. H., Hong, J. P., Hwang, J. A., Ham, B. J., Na, K. S., Kim, W. J., et al. (2015). Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. *Psychiatry Res.* 228, 95–99. doi: 10.1016/j.psychres.2015.04.020

Lélu, M., Villena, I., Dardé, M. L., Aubert, D., Geers, R., Dupuis, E., et al. (2012). Quantitative estimation of the viability of *Toxoplasma gondii* oocysts in soil. *Appl. Environ. Microbiol.* 78, 5127–5132. doi: 10.1128/aem.00246-12

Li, Y., Viscidi, R. P., Kannan, G., McFarland, R., Pletnikov, M. V., Severance, E. G., et al. (2018). Chronic *toxoplasma gondii* infection induces anti-N-methyl-DAspartate receptor autoantibodies and associated behavioral changes and neuropathology. *Infect. Immun.* 86, 1–12. doi: 10.1128/iai.00398-18

Liang, J., Guan, X., Sun, Q., Hao, Y., and Xiu, M. (2024). Neutrophil/lymphocyte ratio and cognitive performances in first-episode patients with schizophrenia and healthy controls. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 135, 111092. doi: 10.1016/j.pnpbp.2024.111092

Lili, Y., Biyun, W., Zihan, Y., Shuyu, Z., Zixuan, X., Shuizhen, W., et al. (2024). *Toxoplasma gondii* infection positively associated with schizophrenia: Evidences from UK Biobank cohort and case-controlled studies. *J. Psychiatr. Res.* 175, 243–250. doi: 10.1016/j.jpsychires.2024.05.025

Liu, Y., Chen, L., Zou, Z., Zhu, B., Hu, Z., Zeng, P., et al. (2016). Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells. *J. Med. Virol.* 88, 1–8. doi: 10.1002/jmv.24504

Liu, Z., Ruter, D. L., Quigley, K., Tanke, N. T., Jiang, Y., and Bautch, V. L. (2021). Single-cell RNA sequencing reveals endothelial cell transcriptome heterogeneity under homeostatic laminar flow. *Arterioscler. Thromb. Vasc. Biol.* 41, 2575–2584. doi: 10.1161/atvbaha.121.316797

Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., et al. (2010). The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. *J. Clin. Invest.* 120, 1914–1924. doi: 10.1172/jci42164

Lizano, P., Pong, S., Santarriaga, S., Bannai, D., and Karmacharya, R. (2023). Brain microvascular endothelial cells and blood-brain barrier dysfunction in psychotic disorders. *Mol. Psychiatry* 2023, 3698–3708. doi: 10.1038/s41380-023-02255-0

Lizano, P., Pong, S., Santarriaga, S., Deepthi, M., Bidmc, B., and Karmacharya, R. (2022). TNF $\alpha$  and MMP1 in brain microvascular endothelial cells regulate blood-brain barrier dysfunction in psychotic disorders. *Preprint*. 30. doi: 10.21203/rs.3.rs-1162029/ v1

Lopes Pinheiro, M. A., Kamermans, A., Garcia-Vallejo, J. J., Van Het Hof, B., Wierts, L., O'Toole, T., et al. (2016). Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration. *Elife.* 5, 1–12. doi: 10.7554/elife.13149

Lucchese, G. (2017). From toxoplasmosis to schizophrenia via NMDA dysfunction: Peptide overlap between Toxoplasma gondii and n-methyl-d-aspartate receptors as a potential mechanistic link. *Front. Psychiatry* 8, 1–8. doi: 10.3389/fpsyt.2017.00037

Lurie, D. I. (2018). An integrative approach to neuroinflammation in psychiatric disorders and neuropathic pain. J. Exp. Neurosci. 12, 1–11. doi: 10.1177/1179069518793639

MacQueen, G. M., and Memedovich, K. A. (2017). Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options. *Psychiatry Clin. Neurosci.* 71, 18–27. doi: 10.1111/pcn.12463

Maenz, M., Schlüter, D., Liesenfeld, O., Schares, G., Gross, U., and Pleyer, U. (2014). Ocular toxoplasmosis past, present and new aspects of an old disease. *Prog. Retin Eye Res.* 39, 77–106. doi: 10.1016/j.preteyeres.2013.12.005

Maes, M., Sirivichayakul, S., Kanchanatawan, B., and Vodjani, A. (2019). Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia. *Neurotox Res.* 36, 306–322. doi: 10.1007/s12640-019-00054-6

Makó, V., Czúcz, J., Weiszhár, Z., Herczenik, E., Matkó, J., Prohászka, Z., et al. (2010). Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1 $\beta$ , TNF- $\alpha$ , and LPS. *Cytom Part A*. 77, 962–970. doi: 10.1002/cyto.a.20952

Maldonado, Y. A., Read, J. S., Byington, C. L., Barnett, E. D., Davies, H. D., Edwards, K. M., et al. (2017). Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. *Pediatrics.* 139. doi: 10.1542/peds.2016-3860

Margreet De Leeuw, A., Brouwer, A., and Knook, D. L. (1990). Sinusoidal endothelial cells of the liver: Fine structure and function in relation to age. *J. Electron Microsc Tech.* 14, 218–236. doi: 10.1002/jemt.1060140304

McCutcheon, R. A., Abi-Dargham, A., and Howes, O. D. (2019). Schizophrenia, dopamine and the striatum: from biology to symptoms. *Trends Neurosci.* 42, 205–220. doi: 10.1016/j.tins.2018.12.004

Menard, C., Dion-albert, L., Cadoret, A., Collignon, A., Linville, R., and Proulx, C. (2024). Pericytes modulate brain vascular integrity in social stress and depression. *PREPRINT (Version 1).* doi: 10.21203/rs.3.rs-5060339/v1

Mesquita, R. T., Ziegler, Ă. P., Hiramoto, R. M., Vidal, J. E., and Pereira-Chioccola, V. L. (2010). Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. *J. Med. Microbiol.* 59, 641–647. doi: 10.1099/jmm.0.016261-0

Meurer Y da, S. R., Brito Rm de, M., da Silva, V. P., Andade Jm de, A., Linhares, S. S. G., Junior, A. P., et al. (2020). *Toxoplasma gondii* infection damages the perineuronal nets in a murine model. *Mem Inst Oswaldo Cruz.* 115, 1–7. doi: 10.1590/0074-02760200007

Meyer, J. M., McEvoy, J. P., Davis, V. G., Goff, D. C., Nasrallah, H. A., Davis, S. M., et al. (2009). Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. *Biol. Psychiatry* 66, 1013–1022. doi: 10.1016/j.biopsych.2009.06.005

Mitchell, J. A., Shala, F., Pires, M. E. L., Loy, R. Y., Ravendren, A., Benson, J., et al. (2021). Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation. *Sci. Adv.* 7, 18–20. doi: 10.1126/sciadv.abf6054

Montoya, J. G., and Remington, J. S. (2008). Clinical Practice: Management of *Toxoplasma gondii* Infection during Pregnancy. *Clin. Infect. Dis.* 47, 554–566. doi: 10.1086/590149

Moraes Lm de, B., Raimundo, J. M., Guimarães, A., Santos, H. A., Macedo Junior G de, L., Massard, C. L., et al. (2011). Occurrence of anti-Neospora caninum and anti-*Toxoplasma gondii* IgG antibodies in goats and sheep in western Maranhão, Brazil. *Rev. Bras. Parasitol. Veterinária.* 20, 312–317. doi: 10.1590/S1984-29612011000400010

Morais, F. B., Arantes, T. E. F. E., and Muccioli, C. (2019). Seroprevalence and manifestations of ocular toxoplasmosis in patients with schizophrenia. *Ocul Immunol. Inflamm.* 27, 134–137. doi: 10.1080/09273948.2017.1408843

Moussiopoulou, J., Yakimov, V., Rauchmann, B. S., Toth, H., Melcher, J., Jäger, I., et al. (2023). Increased blood-brain barrier leakage in schizophrenia spectrum disorders compared to healthy controls in dynamic contrast-enhanced magnetic resonance imaging. *medRxiv*. 27. doi: 10.1101/2023.12.12.23299782

Mouveaux, T., Roger, E., Gueye, A., Eysert, F., Huot, L., Grenier-Boley, B., et al. (2021). Primary brain cell infection by Toxoplasma gondii reveals the extent and dynamics of parasite differentiation and its impact on neuron biology. *Open Biol.* 11. doi: 10.1098/rsob.210053

Mugisho, O. O., Robilliard, L. D., Nicholson, L. F. B., Graham, E. S., and O'Carroll, S. J. (2020). Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. *Cell Biol. Int.* 44, 343–351. doi: 10.1002/cbin.11232

Nagata, T., Dwyer, C. A., Yoshida-Tanaka, K., Ihara, K., Ohyagi, M., Kaburagi, H., et al. (2021). Cholesterol-functionalized DNA/RNA heteroduplexes cross the bloodbrain barrier and knock down genes in the rodent CNS. *Nat. Biotechnol.* 39, 1529–1536. doi: 10.1038/s41587-021-00972-x

Najjar, S., Pahlajani, S., De Sanctis, V., Stern, J. N. H., Najjar, A., and Chong, D. (2017). Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology: A theoretical integration of clinical and experimental evidence. *Front. Psychiatry* 8. doi: 10.3389/fpsyt.2017.00083

Navia, B. A., Petito, C. K., Gold, J. W. M., Cho E., -S., Jordan, B. D., and Price, R. W. (1986). Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: Clinical and neuropathological findings in 27 patients. *Ann. Neurol.* 19, 224–238. doi: 10.1002/ana.410190303

Nguyen, T. T., Dev, S. I., Chen, G., Liou, S. C., Martin, A. S., Irwin, M. R., et al. (2018). Abnormal levels of vascular endothelial biomarkers in schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* 268, 849–860. doi: 10.1007/s00406-017-0842-6

Niebuhr, D. W., Millikan, A. M., Cowan, D. N., Yolken, R., Li, Y., and Weber, N. S. (2008). Selected infectious agents and risk of schizophrenia among U.S. military personnel. *Am. J. Psychiatry* 165, 99–106. doi: 10.1176/appi.ajp.2007.06081254

Nikolakopoulou, A. M., Montagne, A., Kisler, K., Dai, Z., Wang, Y., Huuskonen, M. T., et al. (2019). Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. *Nat. Neurosci.* 22, 1089–1098. doi: 10.1038/s41593-019-0434-z

Northoff, G., Richter, A., Bermpohl, F., Grimm, S., Martin, E., Marcar, V. L., et al. (2005). NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. *Schizophr. Res.* 72, 235–248. doi: 10.1016/j.schres.2004.04.009

Oldenhove, G., Bouladoux, N., Wohlfert, E. A., Hall, J. A., Chou, D., Dos, L., et al. (2009). Article decrease of foxp3 + Treg cell number and acquisition of effector cell phenotype during lethal infection. *Immunity*. 31, 772–786. doi: 10.1016/j.immuni.2009.10.001

Omer, L. (2022). Seroprevalence and correlation between Toxoplasmosis and Schizophrenic patients in Sulaimania city, Iraq. *Diyala J. Pure Sci.* 18, 17–27. doi: 10.24237/djps.1802.574a

Omran, Z., Whitehouse, C., Halwani, M., Zamzami, M., Baothman, O. A., and Rauch, C. (2020). Pinocytosis as the biological mechanism that protects pgp function in multidrug resistant cancer. *Symmetry (Basel).* 12, 1–10. doi: /10.3390/sym12081221

Parellada, E., and Gassó, P. (2021). Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. *Transl. Psychiatry* 11. doi: 10.1038/s41398-021-01385-9

Parlog, A., Harsan, L. A., Zagrebelsky, M., Weller, M., Von Elverfeldt, D., Mawrin, C., et al. (2014). Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity. *DMM Dis. Model. Mech.* 7, 459–469. doi: 10.1242/dmm.014183

Pérez-Cremades, D., Bueno-Betí, C., García-Giménez, J. L., Ibañez-Cabellos, J. S., Hermenegildo, C., Pallardó, F. V., et al. (2017). Extracellular histones disarrange vasoactive mediators release through a COX-NOS interaction in human endothelial cells. *J. Cell Mol. Med.* 21, 1584–1592. doi: 10.1111/jcmm.13088

Petroff, O. A. C., Rothman, D. L., Behar, K. L., and Mattson, R. H. (1996). Low brain GABA level is associated with poor seizure control. *Ann. Neurol.* 40, 908–911. doi: 10.1002/ana.410400613

Pieper, C., Marek, J. J., Unterberg, M., Schwerdtle, T., and Galla, H. J. (2014). Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS. *vitro. Brain Res.* 1550, 1–8. doi: 10.1016/j.brainres.2014.01.004

Pillai, A., Howell, K. R., Ahmed, A. O., Weinberg, D., Allen, K. M., Bruggemann, J., et al. (2015). Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. *Mol. Psychiatry* 21, 1–7. doi: 10.1038/mp.2015.96

Pinjari, O. F., Dasgupta, S. K., and Okusaga, O. O. (2022). Plasma soluble P-selectin, interleukin-6 and S100B protein in patients with schizophrenia: a pilot study. *Psychiatr. Q.* 93, 335–345. doi: 10.1007/s11126-021-09954-3

Poller, B., Gutmann, H., Krähenbühl, S., Weksler, B., Romero, I., Couraud, P. O., et al. (2008). The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. *J. Neurochem.* 107, 1358–1368. doi: 10.1111/j.1471-4159.2008.05730.x

Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., and Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. *Biol. Psychiatry* 63, 801–808. doi: 10.1016/j.biopsych.2007.09.024

Prandovszky, E., Gaskell, E., Martin, H., Dubey, J. P., Webster, J. P., and McConkey, G. A. (2011). The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. *PLoS One* 6. doi: 10.1371/journal.pone.0023866

Price, G. W., Chadjichristos, C. E., Kavvadas, P., Tang, S. C. W., Yiu, W. H., Green, C. R., et al. (2020). Blocking Connexin-43 mediated hemichannel activity protects against early tubular injury in experimental chronic kidney disease. *Cell Commun. Signal.* 18, 1–17. doi: 10.1186/s12964-020-00558-1

Proescholdt, M. A., Heiss, J. D., Walbridge, S., Mühlhauser, J., Capogrossi, M. C., Oldfield, E. H., et al. (1999). Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. *J. Neuropathol. Exp. Neurol.* 58, 613–627. doi: 10.1097/00005072-199906000-00006

Pu, J., Liu, Y., Gui, S., Tian, L., Xu, S., Song, X., et al. (2020). Vascular endothelial growth factor in major depressive disorder, schizophrenia, and bipolar disorder: A network meta-analysis. *Psychiatry Res.* 292, 113319. doi: 10.1016/j.psychres.2020.113319

Radu, G., Luca, C., Petrescu, L., Bordejevic, D. A., Tomescu, M. C., Andor, M., et al. (2020). The predictive value of endothelial inflammatory markers in the onset of schizophrenia. *Neuropsychiatr. Dis. Treat.* 16, 545–555. doi: 10.2147/NDT.S240349

Rempe, R. G., Hartz, A. M. S., Soldner, E. L. B., Sokola, B. S., Alluri, S. R., Abner, E. L., et al. (2018). Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy. *J. Neurosci.* 38, 4301–4315. doi: 10.1523/jneurosci.2751-17.2018

Sabin, A. B., and Olitsky, P. K. (1937). Toxoplasma and obligate intracellular parasitism. Sci. (80-). 85, 336-338. doi: 10.1126/science.85.2205.336

Safarpour, H., Cevik, M., Zarean, M., Barac, A., Hatam-Nahavandi, K., Rahimi, M. T., et al. (2020). Global status of *Toxoplasma gondii* infection and associated risk factors in people living with HIV. *Aids* 34, 469–474. doi: 10.1097/qad.00000000002424

Šagud, M., Madžarac, Z., Nedic Erjavec, G., Šimunović Filipčić, I., Mikulić, F. L., Rogić, D., et al. (2023). The associations of neutrophil–lymphocyte, platelet– lymphocyte, monocyte–lymphocyte ratios and immune-inflammation index with negative symptoms in patients with schizophrenia. *Biomolecules*. 13. doi: 10.3390/ biom13020297

Sasongko, M. B., Wong, T. Y., Jenkins, A. J., Nguyen, T. T., Shaw, J. E., and Wang, J. J. (2014). Research : Complications Circulating markers of inflammation and endothelial function, and their relationship to diabetic retinopathy. *Diabetes Med.* 32, 686–691. doi: 10.1111/dme.12640

Sawyer, A. J., Tian, W., Saucier-Sawyer, J. K., Rizk, P. J., Saltzman, W. M., Bellamkonda, R. V., et al. (2014). The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. *Biomaterials*. 35, 6698–6706. doi: 10.1016/j.biomaterials.2014.05.008

Scharton-Kersten, T. M., Yap, G., Magram, J., Sher, A., Scharton-kersten, B. T. M., Yap, G., et al. (1997). Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen *Toxoplasma gondii. J. Exp. Med.* 185, 1261–1273. doi: 10.1084/jem.185.7.1261

Schmidley, J. W., and Wissig, S. L. (1986). Anionic sites on the luminal surface of fenestrated and continuous capillaries of the CNS. *Brain Res.* 363, 265–271. doi: 10.1016/0006-8993(86)91011-5

Schroeter, M. L., Abdul-Khaliq, H., Frühauf, S., Höhne, R., Schick, G., Diefenbacher, A., et al. (2003). Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. *Schizophr. Res.* 62, 231–236. doi: 10.1016/s0920-9964(02) 00383-3

Schwarz, M. K., Riedel, M., Ackenheil, M., and Müller, N. (2000). Decreased levels of soluble intercellular adhesion Molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. *Biol. Psychiatry* 47, 29–33. doi: 10.1016/s0006-3223(99)00206-1

Semiz, M., Yildirim, O., Canan, F., Demir, S., Hasbek, E., Tuman, T. C., et al. (2014). Elevated neutrophil/lymphocyte ratio in patients with schizophrenia. *Psychiatr. Danub.* 26, 220–225.

Semkovska, M., Quinlivan, L., O'Grady, T., Johnson, R., Collins, A., O'Connor, J., et al. (2019). Cognitive function following a major depressive episode: a systematic review and meta-analysis. *Lancet Psychiatry* 6, 851–861. doi: 10.1016/s2215-0366(19)30291-3

Sheikh, M. A., O'Connell, K. S., Lekva, T., Szabo, A., Akkouh, I. A., Osete, J. R., et al. (2023). Systemic cell adhesion molecules in severe mental illness: potential role of

intercellular CAM-1 in linking peripheral and neuroinflammation. *Biol. Psychiatry* 93, 187–196. doi: 10.1016/j.biopsych.2022.06.029

Silva, N. M., Vieira, J. C. M., Carneiro, C. M., and Tafuri, W. L. (2009). *Toxoplasma gondii*: The role of IFN-gamma, TNFRp55 and iNOS in inflammatory changes during infection. *Exp. Parasitol.* 123, 65–72. doi: 10.1016/j.exppara.2009.05.011

Siragusa, M., Oliveira Justo, A. F., Malacarne, P. F., Strano, A., Buch, A., Withers, B., et al. (2021). VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes. *Cardiovasc. Res.* 117, 1546–1556. doi: 10.1093/cvr/cvaa213

Stankovic, I., Notaras, M., Wolujewicz, P., Lu, T., Lis, R., Ross, M. E., et al. (2024). Schizophrenia endothelial cells exhibit higher permeability and altered angiogenesis patterns in patient-derived organoids. *Transl. Psychiatry* 14, 1–15. doi: 10.1038/s41398-024-02740-2

Stefanović, M. P., Petronijević, N., Dunjić-Kostić, B., Velimirović, M., Nikolić, T., Jurišić, V., et al. (2016). Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia. *J. Psychiatr. Res.* 73, 45–52. doi: 10.1016/j.jpsychires.2015.11.002

Stepanova, E. V., Kondrashin, A. V., Sergiev, V. P., Morozova, L. F., Turbabina, N. A., Maksimova, M. S., et al. (2019). Toxoplasmosis and mental disorders in the Russian Federation (with special reference to schizophrenia). *PLoS One* 14, 1–10. doi: 10.1371/journal.pone.0219454

Su, T., Yang, Y., Lai, S., Jeong, J., Jung, Y., McConnell, M., et al. (2021). Single-cell transcriptomics reveals zone-specific alterations of liver sinusoidal endothelial cells in cirrhosis. *Cmgh.* 11, 1139–1161. doi: 10.1016/j.jcmgh.2020.12.007

Sun, J., Ou, W., Han, D., Paganini-Hill, A., Fisher, M. J., and Sumbria, R. K. (2022). Comparative studies between the murine immortalized brain endothelial cell line (bEnd.3) and induced pluripotent stem cell-derived human brain endothelial cells for paracellular transport. *PLoS One* 17, 1–17. doi: 10.1371/journal.pone.0268860

Sutterland, A. L., Fond, G., Kuin, A., Koeter, M. W. J., Lutter, R., van Gool, T., et al. (2015). Beyond the association. *Toxoplasma gondii* in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis. *Acta Psychiatr. Scand.* 132, 161–179. doi: 10.1111/acps.12423

Suzuki, Y., Lutshumba, J., Chen, K. C., Abdelaziz, M. H., Sa, Q., and Ochiai, E. (2023). IFN- $\gamma$  production by brain-resident cells activates cerebral mRNA expression of a wide spectrum of molecules critical for both innate and T cell-mediated protective immunity to control reactivation of chronic infection with Toxoplasma gondii. *Front. Cell Infect. Microbiol.* 13, 1–15. doi: 10.3389/fcimb.2023.1110508

Tabaie, E. Z., Gao, Z., Gomes, S., Bergensen, K., Zhong, W., and Wilson, E. H. (2024). *Toxoplasma gondii* infection of neurons alters the production and content of extracellular vesicles altering astrocyte phenotype and contributing to the loss of GLT-1 in the infected brain. *bioRxiv*. doi: 10.1101/2024.11.08.622601

Ueno, N., Harker, K. S., Clarke, E. V., McWhorter, F. Y., Liu, W. F., Tenner, A. J., et al. (2014). Real-time imaging of Toxoplasma-infected human monocytes under fluidic shear stress reveals rapid translocation of intracellular parasites across endothelial barriers. *Cell Microbiol.* 16, 580–595. doi: 10.1111/cmi.12239

Uranova, N. A., Zimina, I. S., Vikhreva, O. V., Krukov, N. O., Rachmanova, V. I., and Orlovskaya, D. D. (2010). Ultrastructural damage of capillaries in the neocortex in schizophrenia. *World J. Biol. Psychiatry* 11, 567–578. doi: 10.3109/15622970903414188

Urich, E., Lazic, S. E., Molnos, J., Wells, I., and Freskgård, P. O. (2012). Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive *in vitro* blood-brain barrier models. *PLoS One* 7. doi: 10.1371/ journal.pone.0038149

Van Berlekom, A. B., Muflihah, C. H., Snijders, G. J. L. J., MacGillavry, H. D., Middeldorp, J., Hol, E. M., et al. (2020). Synapse pathology in schizophrenia: A metaanalysis of postsynaptic elements in postmortem brain studies. *Schizophr. Bull.* 46, 374–386. doi: 10.1093/schbul/sbz060

Vostrikov, V., Orlovskaya, D., and Uranova, N. (2008). Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. *World J. Biol. Psychiatry* 9, 34–42. doi: 10.1080/15622970701210247

Vyas, A., Kim, S. K., Giacomini, N., Boothroyd, J. C., and Sapolsky, R. M. (2007). Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. *Proc. Natl. Acad. Sci. U S A.* 104, 6442–6447. doi: 10.1073/ pnas.0608310104

Waheed, H. J., Abdul, H., Hadi, R., and Shafek, M. A. (2016). Vascular endothelial growth factor as predictive marker for hypertension in Iraqi adults patients. *Mustansiriya Med. J.* 15, 56–59. doi: 10.4103/2070-1128.247892

Wang, T., Sun, X., Qin, W., Zhang, X., Wu, L., Li, Y., et al. (2019). From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with. *Toxoplasma gondii*. *Behav. Brain Res.* 359, 737–748. doi: 10.1016/j.bbr.2018.09.011

Webster, J. P. (1994). Prevalence and transmission of *Toxoplasma gondii* in wild brown rats, Rattus norvegicus. *Parasitology*. 108, 407-411. doi: 10.1017/s0031182000075958

Weickert, C. S., Fung, S. J., Catts, V. S., Schofield, P. R., Allen, K. M., Moore, L. T., et al. (2013). Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. *Mol. Psychiatry* 18, 1185–1192. doi: 10.1038/mp.2012.137

Weight, C. M., and Carding, S. R. (2012). The protozoan pathogen *Toxoplasma gondii* targets the paracellular pathway to invade the intestinal epithelium. *Ann. N Y Acad. Sci.* 1258, 135–142. doi: 10.1111/j.1749-6632.2012.06534.x

Wheway, J., Obeid, S., Couraud, P. O., Combes, V., and Grau, G. E. R. (2013). The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation. *PLoS One* 8, 1–8. doi: 10.1371/journal.pone.0052586

Wiesmann, M., Wandinger, K. P., Missler, U., Eckhoff, D., Rothermundt, M., Arolt, V., et al. (1999). Elevated plasma levels of S-100b protein in schizophrenic patients. *Biol. Psychiatry* 45, 1508–1511. doi: 10.1016/s0006-3223(98)00217-0

Wilhelms, D. B., Kirilov, M., Mirrasekhian, E., Eskilsson, A., Kugelberg, U. O., Klar, C., et al. (2014). Deletion of prostaglandin E2 synthesizing enzymes in brain endothelial cells attenuates inflammatory fever. *J. Neurosci.* 34, 11684–11690. doi: 10.1523/JNEUROSCI.1838-14.2014

Woodman, J. P., Dimier, I. H., and Bout, D. T. (1991). Human endothelial cells are activated by IFN-gamma to inhibit *Toxoplasma gondii* replication. Inhibition is due to a different mechanism from that existing in mouse macrophages and human fibroblasts. *J. Immunol.* 147, 2019–2023. doi: 10.4049/jimmunol.147.6.2019

World Health Organization (2022a). *Mental disorders*. Available online at: http:// 1drv.ms/1D5ikaA%5Cnother/archive\_1.pdf (Accessed May 13, 2024).

World Health Organization (2022b). *Schizophrenia*. Available online at: https:// www.who.int/news-room/fact-sheets/detail/schizophrenia?gclid=CjwKCAjw vfmoBhAwEiwAG2tqzPViCRuLi3ZC9PHKxfvtisWWo1u7VdhDidtaDoSWX 0UYaVNlfYge4hoCCPQQAvD\_BwE (Accessed May 13, 2024).

Xiao, J., Li, Y., Gressitt, K. L., He, H., Kannan, G., Schultz, T. L., et al. (2016). Cerebral complement C1q activation in chronic Toxoplasma infection. *Brain Behav. Immun.* 58, 52–56. doi: 10.1016/j.bbi.2016.04.009

Xiao, W., Zhan, Q., Ye, F., Tang, X., Li, J., Dong, H., et al. (2018). Baseline serum vascular endothelial growth factor levels predict treatment response to antipsychotic medication in patients with schizophrenia. *Eur. Neuropsychopharmacol.* 28, 603–609. doi: 10.1016/j.euroneuro.2018.03.007

Xiao, W., Zhan, Q., Ye, F., Tang, X., Li, J., Dong, H., et al. (2019). Elevated serum vascular endothelial growth factor in treatment-resistant schizophrenia treated with electroconvulsive therapy: Positive association with therapeutic effects. *World J. Biol. Psychiatry* 20, 150–158. doi: 10.1080/15622975.2018.1459048

Yamamori, H., Hashimoto, R., Ishima, T., Kishi, F., Yasuda, Y., Ohi, K., et al. (2013). Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. *Neurosci. Lett.* 556, 37–41. doi: 10.1016/j.neulet.2013.09.059 Yuksel, P., Alpay, N., Babur, C., Bayar, R., Saribas, S., Karakose, A. R., et al. (2010). The role of latent toxoplasmosis in the aetiopathogenesis of schizophrenia - The risk factor or an indication of a contact with cat? *Folia Parasitol. (Praha).* 57, 121–128. doi: 10.14411/fp.2010.015

Zeng, J., Zhang, T., Tang, B., Li, S., Yao, L., Bishop, J. R., et al. (2024). Choroid plexus volume enlargement in first-episode antipsychotic-naïve schizophrenia. *Schizophrenia*. 10, 1–6. doi: 10.1038/s41537-023-00424-2

Zhang, Y., Catts, V. S., Sheedy, D., McCrossin, T., Kril, J. J., and Shannon Weickert, C. (2016). Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. *Transl. Psychiatry* 6, 1–10. doi: 10.1038/tp.2016.238

Zhang, X., Liu, X., Shang, H., Xu, Y., and Qian, M. (2011). Monocyte chemoattractant protein-1 induces endothelial cell apoptosis *in vitro* through a p53-dependent mitochondrial pathway. *Acta Biochim. Biophys. Sin.* 43, 787–795. doi: 10.1093/abbs/gmr072

Zhao, F., Li, B., Yang, W., Ge, T., and Cui, R. (2022). Brain–immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders. *Cell Prolif.* 55. doi: 10.1111/cpr.13295

Zhao, Y., Xiao, W., Chen, K., Zhan, Q., Ye, F., Tang, X., et al. (2019). Neurocognition and social cognition in remitted first-episode schizophrenia: Correlation with VEGF serum levels. *BMC Psychiatry* 19, 1–8. doi: 10.1186/s12888-019-2397-8

Zhou, Y. F., Huang, J. C., Zhang, P., Fan, F. M., Chen, S., Fan, H. Z., et al. (2020). Choroid plexus enlargement and allostatic load in schizophrenia. *Schizophr. Bull.* 46, 722–731. doi: 10.1093/schbul/sbz100

Zhu, Y., Owens, S. J., Murphy, C. E., Ajulu, K., Rothmond, D., Purves-Tyson, T., et al. (2022). Inflammation-related transcripts define "high" and "low" subgroups of individuals with schizophrenia and bipolar disorder in the midbrain. *Brain Behav. Immun.* 105, 149–159. doi: 10.1016/j.bbi.2022.06.012

Zhu, H., Wang, N., Yao, L., Chen, Q., Zhang, R., Qian, J., et al. (2018). Moderate UV exposure enhances learning and memory by promoting a novel glutamate biosynthetic pathway in the brain. *Cell.* 173, 1716–1727.e17. doi: 10.1016/j.cell.2018.04.014

Zovein, A. C., Hofmann, J. J., Lynch, M., French, W. J., Turlo, K. A., Yang, Y., et al. (2008). Article fate tracing reveals the endothelial origin of hematopoietic stem cells. *Stem Cell.* 3, 625–636. doi: 10.1016/j.stem.2008.09.018

Zuo, R., Ye, L. F., Huang, Y., Song, Z. Q., Wang, L., Zhi, H., et al. (2021). Hepatic small extracellular vesicles promote microvascular endothelial hyperpermeability during NAFLD via novel-miRNA-7. *J. Nanobiotechnology.* 19, 1–19. doi: 10.1186/s12951-021-01137-3